Oruka Therapeutics, Inc. (ORKA): Total Assets
$488.62M
As of 2025-12-31
$1.14B
As of 2026-06-30
+124.7%
3-year compound annual growth
+57.5%
5-year compound annual growth
+28.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $488.62M | +23.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $396.02M | +946.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $37.86M | -12.1% | 2024-02-01, Balance as of period end |
| 2022-12-31 | $43.09M | -21.6% | 2024-02-01, Balance as of period end |
| 2021-12-31 | $54.92M | +8.9% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $50.43M | +490.8% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $8.54M | +25.1% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $6.83M | -44.8% | 2020-02-18, Balance as of period end |
| 2017-12-31 | $12.37M | -49.8% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $24.63M | -37.8% | 2018-03-22, Balance as of period end |
| 2015-12-31 | $39.57M | +145.3% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $16.13M | -5.6% | 2016-03-17, Balance as of period end |
| 2013-12-31 | $17.08M | +431.9% | 2015-03-19, Balance as of period end |
| 2012-12-31 | $3.21M | -50.6% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $6.50M | -20.3% | 2013-03-21, Balance as of period end |
| 2010-12-31 | $8.16M | n/a | 2012-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $488.62M | +23.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $485.57M | +37.1% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $479.51M | +250.2% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $476.17M | +46.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $513.59M | +213.2% |
Compare ORKA, VNDA, TBPH, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗